NewAmsterdam Pharma Company (NAMS) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on NewAmsterdam Pharma Company (NAMS) is Neutral.

The composite score behind that read is -0.13, weighing +0.51 of bullish evidence against -0.27 bearish.

NewAmsterdam Pharma Company last closed at $22.27, -2.32% on the session.

Against the IVW growth benchmark the position is -2.93% over the forecast window.

The read is built from 11 underlying insights — 2 bullish and 9 bearish.

Agreement across those insights is 82%.

NewAmsterdam Pharma Company has no graded predictions yet. We publish our accuracy across thousands of stocks in the open, misses included.

On the fundamentals StockMap ranks NewAmsterdam Pharma Company in the 21st percentile on return on equity, where 100 is best.

NewAmsterdam Pharma Company is classified under Health Care / Biotechnology, with a market capitalisation of $2.73B.

StockMap tracks NewAmsterdam Pharma Company as the 72nd largest of the 365 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 190 Moderate Underperform, 164 Neutral and 11 Strong Underperform.

On that composite NewAmsterdam Pharma Company ranks 96th of 365 in the group, against a group median of -0.21.